Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography

ConclusionThe results of this study suggest that CEUS at 5  weeks after initiation of Atezo + Bev may predict PFS in HCC patients. Changes to the treatment plan may need to be considered in patients with post AUC >  61.3.
Source: Journal of Medical Ultrasonics - Category: Radiology Source Type: research